Salem A, et al. - From November 1, 2017, to February 28, 2018, authors analyzed subjects with limited-stage small cell lung cancer (SCLC) in this post hoc secondary analysis of the Concurrent Once-Daily vs Twice-Daily Radiotherapy Trial (CONVERT), a multicenter phase 3 trial, to estimate the components and consequences among cases with stage I to II SCLC treated with modern chemoradiotherapy. They observed a long-term survival with acceptable toxic effects after chemoradiotherapy and prophylactic cranial irradiation (PCI) in subjects with stage I to II SCLC as compared to cases with stage III disease rendering data that practitioners could possibly give their patients to assist clinical conclusions.